TABLE 1.
Prevalence of baseline polymorphisms in NS3 and NS5A in GT1b-infected patients by population sequencing
| Target and baseline polymorphism | Prevalence (%; n/N)a in: |
|
|---|---|---|
| Japanese patients | Western patients | |
| NS3 | ||
| T54S | 3.3 (14/424) | 1.6 (6/371) |
| V55A/I | 0.2 (1/424) | 1.0 (4/371) |
| Y56F | 36.1 (153/424) | 33.4 (124/371) |
| Q80H/I/K/M/R | 2.1 (9/424) | 0.3 (1/371) |
| Q80L | 10.6 (45/424) | 5.1 (19/371) |
| S122A/C/D/I/N/R/T/V/Y | 10.9 (46/424) | 10.8 (40/371) |
| S122G | 26.2 (111/424) | 5.1 (19/371) |
| A156T/V | 0.5 (2/371) | |
| D168E | 1.2 (5/424) | 0.3 (1/371) |
| NS5A | ||
| L28I/V | 0.7 (3/431) | |
| L28 M | 8.8 (38/431) | 1.3 (5/391) |
| R30G/H/L | 0.7 (3/431) | 0.5 (2/391) |
| R30Q | 12.8 (55/431) | 7.2 (28/391) |
| L31F/I/M | 2.8 (12/431) | 5.1 (20/391) |
| Q54A/C/D/E/H/K/L/N/P/R/S/V/Y | 43.9 (189/431) | 45.3 (177/391) |
| P58A/L/Q/R/S/T | 7.4 (32/431) | 7.4 (29/391) |
| Q62A/C/D/E/H/K/L/M/N/P/R/S/Y | 9.7 (42/431) | 10.0 (39/391) |
| A92E/K/M/S/T/V | 7.4 (32/431) | 4.9 (19/391) |
| Y93C/H/S | 12.5 (54/431) | 7.7 (30/391) |
a
Data are percentages of subjects with variants at the corresponding amino acid position. n, number of subjects with baseline variant; N, total number of samples sequenced.